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New insights into HCV replication in
original cells from Aedes mosquitoes
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Pascal Fender1, Patrice Morand2, Imre Berger5*, Marie-Anne Petit6* and Emmanuel Drouet1*
Abstract
Background: The existing literature about HCV association with, and replication in mosquitoes is extremely poor.
To fill this gap, we performed cellular investigations aimed at exploring (i) the capacity of HCV E1E2 glycoproteins
to bind on Aedes mosquito cells and (ii) the ability of HCV serum particles (HCVsp) to replicate in these cell lines.
Methods: First, we used purified E1E2 expressing baculovirus-derived HCV pseudo particles (bacHCVpp) so we
could investigate their association with mosquito cell lines from Aedes aegypti (Aag-2) and Aedes albopictus (C6/36).
We initiated a series of infections of both mosquito cells (Ae aegypti and Ae albopictus) with the HCVsp (Lat strain -
genotype 3) and we observed the evolution dynamics of viral populations within cells over the course of infection
via next-generation sequencing (NGS) experiments.
Results: Our binding assays revealed bacHCVpp an association with the mosquito cells, at comparable levels
obtained with human hepatocytes (HepaRG cells) used as a control. In our infection experiments, the HCV RNA (+)
were detectable by RT-PCR in the cells between 21 and 28 days post-infection (p.i.). In human hepatocytes HepaRG
and Ae aegypti insect cells, NGS experiments revealed an increase of global viral diversity with a selection for a
quasi-species, suggesting a structuration of the population with elimination of deleterious mutations. The
evolutionary pattern in Ae albopictus insect cells is different (stability of viral diversity and polymorphism).
Conclusions: These results demonstrate for the first time that natural HCV could really replicate within Aedes
mosquitoes, a discovery which may have major consequences for public health as well as in vaccine development.
Keywords: Hepatitis C virus (HCV), HCV pseudo particles, Aedes aegypti, Aedes albopictus, Human hepatocytes
Background
Hepatitis C Virus (HCV) is a member of the Hepacivirus
genus which belongs to the Flaviviridae family. It is an
enveloped single stranded RNA virus which is present
worldwide [1]. Most of the Flaviviruses are causative
agents for major epidemic or endemic diseases including
Yellow Fever (YF), Dengue Fever (DEN), West Nile Fever
(WN), and recently Zika Virus Disease [2, 3]. Most of
these viruses are transmitted by vectors in very different
epidemiological ways. Some diseases are typically human
(or linked to primates) and do not affect animals (e.g.
DEN). Others are zoonotic and affect humans acciden-
tally, e.g. Japanese Encephalitis, Saint-Louis Encephalitis
and WN. Finally, certain Flaviviruses can circulate in
epidemic form both in human and animal populations
(e.g. YF). These different epidemiological modes of
transmission share in common viral amplification in in-
sect cells, therefore the denomination ‘arbovirus’ [4].
HCV is a severe pathogen, giving rise to liver inflam-
mation and causing acute or chronic disease. New
drugs targeting HCV are now becoming available, but
notwithstanding, HCV infected 180 million people
worldwide in 2013 [5]. Attempts to develop a prophy-
lactic vaccine against HCV which could prevent infec-
tion have largely failed to date [5]. HCV was identified
30 years ago, but its origin remains elusive. HCV is a
blood-borne virus and the epidemic appears to have
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been fueled by new parenteral transmission routes associ-
ated with blood transfusions, immunization, and more re-
cently intravenous drug abuse [6]. The immediate source
of HCV associated with its pandemic spread has been
identified to the areas of the central and west sub-Saharan
Africa [7], as well as south and south-east Asia, where
genetically diverse variants of HCV appear to have circu-
lated for several hundred years [8].
Many different in vitro models have been developed to
investigate HCV. For example, virus-like particles (VLPs)
comprising HCV core proteins and the E1E2 heterodi-
meric envelope glycoproteins were produced in insect
cells [9] and used for immunization of chimpanzees [10].
Furthermore, rhabdoviral (Vesicular Stomatitis Virus,
VSV) [11] and retroviral (Lentivirus or Murine Leukemia
Virus) systems have been utilized to obtain pseudotypes
or so-called HCV pseudo particles (HCVpp) from mam-
malian cells [12]. These mammalian-cell derived pseudo
particles have been instrumental for characterizing HCV
specific neutralizing antibodies [13]. In contrast to HCV-
VLPs, HCVpps are made of a heterologous core formed
by a retroviral protein (e.g. gag), and display the HCV
E1E2 proteins on their surface (Fig. 1a) [9]. HCVpp, simi-
lar to HCV-VLPs, cannot undergo a complete viral life
cycle, notably as they are replication incompetent for lack
of viral genomic RNA [14]. These particles are highly
useful for studying HCV binding and entry, as shown in
Huh-7 cells by means of GFP-labeling approaches [15].
Other robust HCV models called HCVcc (HCV “cell cul-
tured”) have been developed. This system based initially
on transfection of HCV-JFH1 clone genotype 2a RNA in
the human hepatoma cell line (Huh-7 and derivatives) has
demonstrated its efficiency to produce complete infectious
viral particles by infection route [14].
Several HCV risk factors have been defined in the
context of the spreading epidemic and its possible con-
trol. Thus, the reservoir was described as only human
and more generally primates, and the HCV contamin-
ation route was assumed to be mainly through blood
contact. However, for a non-negligible proportion (more
than 20%) of HCV infections the route of transmission
could not be established with confidence [16]. In some
cases, especially regarding the endemic HCV transmis-
sion, alternative routes for spreading HCV could exist.
This hidden HCV epidemic, notably in the USA, repre-
sents a significant socio-economic damage potential,
causing considerable alarm [17]. As a consequence, in-
vestigations on HCV transmission modes merit further
consideration. Taken together, the currently available
results regarding the spread of HCV remain contradict-
ory and their interpretation is a matter of intense de-
bate [18–21]. In 2001, we demonstrated previously that
the AP61 mosquito cell line from Aedes pseudoscutel-
laris could associate with HCV particles [22]. We set
out here to investigate alternative transmission routes for
HCV that could account for the hidden HCV epidemic.
For this purpose, we performed cellular investigations;
first we explored the binding step of HCV by using
baculovirus-derived HCV pseudo particles (bacHCVpp)
[23, 24]; second, we engaged a series of infections of both
mosquito cells (Ae aegypti and Ae albopictus) with serum-
derived HCV particles (Lat strain of genotype 3) [25] and
we followed up the evolution dynamics of viral popula-
tions within cells over the course of infection, through
next-generation sequencing (NGS) experiments.
Methods
Cell cultures
HepaRG cells were cultured as previously described
[25, 26] and using HepaRG® Culture kit for HCV infec-
tion (catalog number: KIT902, Biopredic International).
Aedes albopictus C6/36 cells were grown in Leibovitz
L15 medium and Aedes aegypti Aag-2 cells in Schnei-
der medium (GIBCO Life Technologies). Differentiated
HepaRG cells were seeded in a 6-well tissue culture
(TC) plate and grown in monolayer for two weeks [25].
Mosquito cells were plated after four passages in 4-well
Lab-Tek TC plates. The Aedes aegypti Ktmos1 cells
were generated as previously described [27] and cultivated
in Leibovitz L15 growth medium supplemented with 20%
fetal bovine serum, 1% penicillin- streptomycin, 1% L-glu-
tamine (see Additional file 1 and Additional files 2
and 3: Figure S1 and S2).
MultiBac-based production of HCV pseudo particles
(bacHCVpp)
Recombinant bacHCVpp were produced using the
MultiBac system we developed for multiprotein appli-
cations [23]. HCV E1E2 envelope proteins and HIV gag
protein were cloned into transfer plasmid pOmniBac1
[28] and inserted via Tn7 transposition into the EmBacY
baculoviral genome [23, 28]. Transfection, virus ampli-
fication and recombinant bacHCVpp expression were
performed following established standard operating
procedures [24]. Briefly, bacHCVpp were produced in
250 mL of Sf21 (Spodoptera frugiperda) cells cultured
in suspension in serum-free medium. A gene encoding
for yellow fluorescent protein (YFP) is present in the
EMBacY baculoviral genome, to be used as a reporter
for virus performance and recombinant protein produc-
tion. When YFP fluorescence reached a plateau, the
supernatant was collected, cleared from cells and cell
debris by centrifugation and filtration, and pelleted by
ultracentrifugation at 130,000 g overnight in a swinging
bucket rotor. The bacHCVpp pellet was resuspended in
phosphate-buffered saline (PBS) and loaded on a 20–60%
continuous sucrose gradient. BacHCVpp was apparent in
the gradient as a unique, visible band and was collected.
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Purified bacHCVpp was analyzed by negative-stain
electron microscopy (EM) to verify structural integrity.
Recombinant baculovirus-derived Influenza Virus pseudo
particles (bacFlupp) were also produced as controls (with
M1 matrix protein instead of HIV gag core protein)
(Additional file 4: Figure S3)
Cell binding assay
Binding assays were performed when the cultures each
reached confluence, with bacHCVpp and also with bac-
Flupp, both produced by using the MultiBac system
[23]. The binding experiments were performed with
20 μl of particles (OD650nm = 0.2). Incubation was for
two hours at 37 °C for the human HepaRG cell culture,
and at 28 °C for the mosquito cell line (Ktmos 1 and
C6/36) cultures. Cells were washed twice with their re-
spective media before further analysis.
Immunofluorescence (IF) assay
Cells were fixed with 2% paraformaldehyde (PFA) for
20 min at 37 °C for the human HepaRG cells and 28 °C
for the both mosquito cell lines, respectively, in the TC
plates. Each well was washed three times with PBS 1×.
Immunofluorescence (IF) assays were performed by
incubation for one hour at 37 °C or 28 °C, respectively,
of each well of the TC plates with anti-E1 (clone H4)
Fig. 1 MultiBac-based HCV pseudo particles (bacHCVpp). a Hepatitis C virus (HCV) and HCV pseudo particles (HCVpp) are shown in a schematic
representation. Glycoprotein E1 is colored in green, glycoprotein E2 in blue, HCV core in red, HIV gag in light green. HCV in contrast to HCVpp
contains also ion channel proteins (p7), lipid droplets on the surface and an RNA genome. b HCVpp was produced with the MultiBac system. A
transfer plasmid (pOmniBac1-HCVpp) was used, containing expression cassettes encoding for HCV E1E2 precursor fusion protein on one hand,
and for HIV gag protein to initiate budding or particles on the other. The EmBacY baculoviral genome was used to infect Sf21 insect cell cultures
for HCVpp production. E1E2, glycoprotein precursor fusion; gag, HIV gag protein; YFP, yellow fluorescent protein; Amp, ampicillin resistance marker;
Kan, kanamycin resistance marker, Gn, gentamycin resistance marker; LacZ, blue/white selection marker to identify recombinant baculoviral genome;
mini-attTn7, attachment site for integration of heterologous genes by Tn7 transposition; Tn7L and Tn7R, DNA recognition sequences for Tn7
transposase; LoxP, inverted imperfect repeat for Cre-LoxP DNA fusion; IRES, internal ribosomal entry site; 3′NCR, 3′ non-coding region. C, E1, E2,
P7, NS2, 3, 4A, 4B, 5A, 5B are HCV proteins. c Results from Western Blot experiments are shown, evidencing HCV E1 and E2 proteins in purified
bacHCVpp. MW, Molecular Weight marker; Anti-E1 (H4), primary antibody specific for E1; Anti-E2 (H47), antibody specific for E2; NHS (Normal
Human Serum). Alkaline phosphatase coupled Anti-IgG was used as secondary antibody. Molecular weights (in kDa) of marker bands are indicated.
d Negative-stain electron micrographs of MultiBac-produced HCVpp (bacHCVpp) are shown. BV denotes baculovirions. Scale bar, 50 nm
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mouse IgG (hybridoma supernatant diluted 1/5) as the
primary antibody. The anti-E1 mouse IgGs which
reacted with bacHCVpp bound to cells were then de-
tected by incubation for one hour with Cy3-coupled
goat anti-mouse IgG (Sigma–Aldrich), at a dilution of
1/1000 using a motorized inverted Olympus IE81
microscope and differential interference contrast (DIC).
Infection experimental protocols
An amount of 50,000 cells has been seeded in Lab-Tek
and 24-well plates with 100,000 cells/mL under a volume
of 500 μl. Insect cells and HepaRG cells were incubated at
28 °C and 37 °C respectively. HCV infection experiments
were carried out using purified HCV serum particles
(HCVsp Lat strain, genotype 3a), which contained 6 × 107
copies of HCV RNA per mL (Amplicor HCV Monitor
test, Roche diagnostics, Meylan, France). HCVs Lat strain
was previously well-characterized and used for binding/in-
fection experiments (see Additional file 1: Table S1) [26]
[25]. HepaRG and C6/36 cells were inoculated 3 days
postplating (p.p.), whereas Ktmos1 cells were infected
20 days p.p. All the cells were infected for 18 h at 37 °C
(C6/36 and HepaRG cells) and 28 °C (Ktmos1 cells) with
105 copies of HCV RNA corresponding to multiplicity of
infection (m.o.i.) of 1. Before infection with the HCVsp,
the particles were resuspended in 500 μl of L15 medium
(insect cells) or of working HepaRG medium 710
(HepaRG® Culture kit for HCV infection, catalog number:
KIT902, Biopredic International, Rennes, France). On day
1 postinfection (p.i.), extensive washings (5 times) of the
cells were done. The medium was changed at day 7 p.p.
and then each week at days 14, 21 and 28. Human Embry-
onic Kidney (HEK) 293 cells, which have been shown not
to bind HCVpp, were also infected by HCVsp Lat strain.
All the experiments of HCV infection were performed in
a P3 facility, and according to protocols described in
Additional file 5: Figure S4.
Detection of HCV RNA (+) by one-step reverse transcription
polymerase chain reaction
After HCV infection, the cells were pelleted at 800 rpm
for 10 min, and all the pellets collected were frozen at
−80°. RNA extraction from the cells was performed in the
P3 lab, by using the kit RNase easy (Qiagen) and turbo
DNase 1 U in a 500 μl volume. Afterwards, the reverse
transcription was performed using primers located in the
5′NCR region of all HCV genotypes (5NC1: GCA GAA
AGC GTC TAG CCA TGG CGT, and 5NC2: CTC GCA
AGC ACC CTA TCA GGC AGT). After a denaturation
step, the RNA template was incubated at 42 °C for 50 min
with 7,5 U Primescript Reverse, then the cDNA was amp-
lified for 45 cycles. The amplicons were analyzed onto an
agarose gel and checked by Sanger sequencing (Additional
file 6: Figure S5).
Investigation of the viral diversity and polymorphism by
NGS
The amplicons corresponding to the amplification of
cDNA were submitted to a 454 GS FLX. An additional
PCR step added adapter and sample-specific multiplex
identifiers in forward strand. Forward amplicon sequen-
cing program was then applied. After filtering out reads
strictly shorter than 200 bp, identifying reads present
more than once in the dataset (multiplicity ≥2) and
trimming the remaining 454 primers from them, we ex-
tracted from each sample a sub-dataset of reads based
on multiplicity in descending order such that we kept at
most one hundred sequences per sample, i.e. the most
frequent reads observed in each sample. We finally
merged sub-datasets obtained and processed them with
a multiple sequence alignment algorithm [29] to com-
pare the evolution of “H”, “K” and “C” (respectively for
HepaRG, Ktmos1 and C6/36 cells) versus the “Lat” one,
the HCV inoculum. We used the R package APE to
compute nucleotide diversity and Tajima’s D statistics
for multiple alignments in the fast format [30, 31].
Nucleotide diversity is a population genetic estimate of
the effective mutation rate, defined as twice the product
of the mutation rate by the number of effectively repli-
cating particles or effective population size. An increase
in nucleotide diversity indicates that the size of the
population increases. Negative values of the Tajima’s D
statistic are indicative of positive selection or popula-
tion expansion after a bottleneck, whereas values close
to zero are observed for populations evolving under
mutation-drift equilibrium. Positive values of the Taji-
ma’s D statistics are indicative of balancing selection or
population divergence. Empirical distributions of nu-
cleotide diversity and Tajima’s D statistic were obtained
after considering 200 random multiple alignments from
the set all viral sequences. The size of the multiple
alignments was equal to the number of haplotypes
detected. Phylogenetic analyses were performed using
neighbor-joining trees and the F84 model of molecular
evolution [32].
Results
HCV envelope proteins associate with Aedes Mosquito
cells lines
We successfully produced recombinant bacHCVpp in
Sf21 insect cell cultures infected with a composite
baculovirus containing two heterologous expression
cassettes, one encoding for the HCV E1E2 precursor
fusion protein, and the other encoding for HIV gag pro-
tein (Fig. 1b). Then we confirmed authentic processing
of the precursor protein and the presence of E1 and E2
on our bacHCVpps by Western Blot (WB) of the sedi-
mented particles and specific antibody staining using
anti-E1 (H4) and anti-E2 (H47) primary monoclonal
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antibodies (Fig. 1c). Two strong signals at 21 kDa and
70 kDa were observed, respectively. Negative stain
electron microscopic (EM) examination of purified
bacHCVpp samples revealed spherical particles decorated
with spikes (Fig. 1d). To determine the functionality of
our purified bacHCVpps, we performed a binding assay
with human hepatocytes, HepaRG cells (Fig. 2). These
cells were already used for the binding [26] and the infec-
tion [25] with serum-derived HCV particles (HCVsp), and
thus can be considered as a robust reference model. The
results showed that bacHCVpps efficiently associate with
human HepaRG hepatocytes in a specific manner, consist-
ent with what was observed for HCVsp [26].
Having established the E1E2 immunological reactiv-
ity, morphological integrity and functionality of our re-
combinant bacHCVpp system, we then asked whether
our bacHCVpps would likewise associate with mos-
quito cell lines. We chose Aedes aegypti Aag-2 (an Ae.
aegypti cell lineage of embryonic origin) [33] and Aedes
albopictus C6/36 cell lines for these experiments. These
cell lines were shown to associate with and be permis-
sive to some other Flaviviruses, including Dengue Virus
(DEN) and Yellow Fever virus (YF) [33, 34]. As shown
in the Fig. 3, we detected clear positive signals for the
two mosquito cell lines. The signals observed for the
human HepaRG hepatocytes (Fig. 2) and for Aedes
aegypti Aag-2 were at a comparable level, while a par-
ticularly strong signal was detected with Aedes albopic-
tus C6/36 cells (Fig. 3).
The specificity of our binding assays were established
either by omitting primary antibody (negative control 1,
Figs. 2 and 3) or by using a non-HCV bacpp derived
from Influenza Virus (bacFlupp) instead of bacHCVpps
(negative control 2, Figs. 2 and 3). Taken together, our
results showed that the signals obtained with human
HepaRG hepatocytes as well as those obtained with the
two different mosquito cell lines, Aedes aegypti Aag-2 and
Aedes albopictus C6/36, are specific for bacHCVpps. This
indicates that the Aedes mosquito cell lines are able to
recognize HCV envelope proteins (E1, E2 and/or E1E2)
expressed on the surface of our bacHCVpps, as well as
human HepaRG hepatocytes. Then, the question is to
know whether these mosquito cells are able to be in vitro
infected with HCVsp, as already demonstrated for human
HepaRG hepatocytes.
Aedes Mosquito cell lines are susceptible to HCVsp
infection
Because we previously showed that HCV envelope was able
to bind to Aedes aegypti and Aedes albopictus cells, we per-
formed infection with HCVsp Lat strain (genotype 3) on
Aedes albopictus C6/36 cell line and Aedes aegypti Ktmos1
cells. The HepaRG cells were used as a reference posi-
tive control. As illustrated in Fig. 4, HCV RNA(+) was
detected by RT-PCR at days 21 and 28 p.i. for HepaRG
cells (Fig. 4a) as well as for the C6/36 mosquito cell line
(Fig. 4b), and at day 28 p.i. for Aedes aegypti Ktmos1
cells (Fig. 4b). All the cells are thus positive for intracel-
lular HCV RNA at day 28 p.i. We will notice negative
results at days 0 and 4 p.i., reflecting production of
newly synthesized HCV RNA molecules. The PCR
products were then subjected to Sanger sequencing.
Mutations were detected within the loops IIb and IIa
for HCV-infected HepaRG and Ktmos1 cells and one
mutation was observed for HCV-infected C6/36 cells
within loop IId of the IRES region of HCV RNA gen-
ome (Additional file 5: Figure S4). Eventually, we did
not obtain any RT-PCR signals at any day explored
(over a period from four days to 28 days) in the HEK
293 experiments (Additional file 7: Figure S6).
Fig. 2 BacHCVpp associate with human hepatocyte cells. Human HepaRG hepatocytes incubated with bacHCVpp for two hours are shown (left).
Binding assay was performed using primary anti-E1 (H4) monoclonal antibody and visualized with Cy3-labeled secondary anti-IgG antibody. Negative
controls are also shown (right). Negative control 1, primary antibody was omitted; negative control 2, bacFlupp was used instead of bacHCVpp. DIC,
Differential Interference Contrast
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Deciphering a divergent evolution of viral strains in Aedes
aegypti cells as in human hepatocytes
Next, we performed a series of next-generation sequen-
cing (NGS) experiments, in order to understand the evo-
lution dynamics of viral populations within cells over the
course of infection, and to support replication within mos-
quito cells. Extraction of the HCV RNA from the inocu-
lum (Lat strain), and the total RNA from HCV-infected
cells at days 21 and 28 p.i. for HepaRG and C6/36 (H21,
H28 and C21 and C28, respectively) and at day 28 p.i. for
Ktmos1 cells (K28) were performed. After processing the
RT-PCR on each sample, the amplicons were sequenced
on a 454 GS FLX Instrument (Roche). Figure 5 shows the
distribution of nucleotide diversity (Fig. A) and Fig. 6
shows the analysis of diversity by the Tajima’s D statistics.
For the HCV strains in HepaRG (Fig. 5a) and Ktmos1
Fig. 3 BacHCVpp associate with Aedes mosquito cell lines C6/36 and Aag-2. Mosquito cells incubated with bacHCVpp for two hours are shown
(left). Binding assay was performed using primary anti-E1 (H4) monoclonal antibody and visualized with Cy3-labeled secondary anti-IgG antibody.
Negative controls are also shown (right). Negative control 1, primary antibody was omitted; negative control 2, bacFlupp was used instead of
bacHCVpp. DIC, Differential Interference Contrast
Fig. 4 Detection of HCV RNA (+) by one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR). HCV RNA (+) was detected by RT-PCR in
non-infected (mock) cells (−) and HCV-infected (+) human HepaRG hepatocytes (a) or insect cells (b, C6/36 Ae. Albopictus and Ktmos1 Ae. Aegypti
cells) collected at days 0 (D0), 4 (D4), 21 (D21) and 28 (D28) p.i. (samples). The inoculum HCVsp (LAT isolate, genotype 3) was used as positive
control (POS) and load in the last lane (A) and just before the last lane (B). MM, molecular weights markers (in Kb). Agarose gels (1%) were
represented and showed products resulting from amplification using 5NC1/2NC2 primers. The specific HCV RNA band corresponded to 243 bp
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(Fig. 5b) cells, the nucleotide diversity increased and the
Tajima’s D increased from negative values to positive
values. By contrast, nucleotide diversity of the strains in
C6/36 (Fig. 5c) cells remained at constant levels and Taji-
ma’s D did not exhibit the same trend as for HepaRG and
Ktmos1.
Then, the phylogenetic analysis of sequences from the
NGS data set was performed, and illustrated in the Fig. 6.
The clades of each reconstructed tree are identified to
their majority group (Lat, H21/H28, K28 and C21/C28). A
divergent evolution of viral strains was evidenced between
the HCV inoculum (Lat, Fig. 6a and b) and H21/H28
(HepaRG, Fig. 6a) and K28 (Ktmos1, Fig. 6b); conversely
there is a lack of evidence for divergence between Lat (Fig.
6c) and C21/C28 (C6/36, Fig. 6c). In HepaRG and Ae
aegypti cells, we detected a selection for a quasispecies,
with an increase of global viral diversity suggesting a
structuration of the population with elimination of dele-
terious mutations (Figs. 5a, b and 6a, b). The evolutionary
pattern in Ae albopictus is different, showing stability of
viral diversity and polymorphism.
Discussion
Very few data have been published about the replication of
HCV in mosquitoes or in any other arthropod, although
various species have been experimented [18–20, 35].
For instance, Hassan et al. detected HCV viral genome
in the heads and midguts of Cx. pipiens from 3 h to
8 days after feeding with HCV infected blood, however
no sequencing was done and it remained impossible to
demonstrate if this was residual or replicated virus.
These last authors concluded that mechanical transmis-
sion was possible due to the presence of HCV RNA in
the mosquito heads after 6 days, but no proofs of HCV
replication was given [35]. More than 12 years ago, we
published the first results demonstrating the binding of
HCV onto Aedes cells. In this last study, we investi-
gated the binding of HCV-positive sera (genotype 1b)
and we concluded mosquito cells (from Aedes pseudos-
cutellaris) could bind HCV and allow HCV replication
for 28 days [22]. At this time the binding of HCV onto
mosquito cells was assessed by HCV RNA detection in
cells 2 h after inoculation and in the last wash of these
Fig. 5 Distributions of nucleotide diversity and Tajima’s D statistics for HCV strains present in the inoculum and HCV-infected cells at days 21 and/
or 28 p.i. Nucleotide diversity increases for the strains in HepaRG (a, H21/H28) and Ktmos1 (b, K28) cells whereas it decreases for the strains in
C6–36 (c, C21/C28) cells. Tajima’s D increases toward 0 for the strains in HepaRG and Ktmos1 cells whereas it does not evolve for the strains in
C6–36 cells
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cells [22]. Because of the HCV infectiousness of serum
samples is highly dependent on host parameters [36, 37],
we used in the present study E1E2-expressing HCVpp
and clearly showed their ability to associate with the mos-
quito cell lines Aedes aegypti (Aag-2) and Aedes albopictus
(C6/36). These results are in agreement with our binding
results published in 2001, but this time we used both the
bacHCVpp and the immunofluoresence in a very specific
manner. So far, no study determined the capacity of the
mosquito cells to bind HCV E1E2 envelope proteins. The
E1E2-expressing HCV pseudo particles were shown to be
excellent HCV models to study viral binding at the cell
surface [12]. HepaRG and liver primary cells have been
described as positive models to bind, incorporate and rep-
licate HCV [25, 26, 36, 38]. The characteristics of several
mosquito cell surface receptors have been described, but
they remain poorly understood. The association of HCV
envelope onto mosquito cells raises some questions about
putative HCV receptors on mosquito cells. Glycosamino-
glycans (GAGs) have been described to bind the HCV
particles in a cooperative fashion to receptors, including
the Low Density Lipoprotein receptor (LDL-R) and the
tetraspanin-family receptor CD81 [15] [39, 40]. Moreover,
a number of studies have implicated cell surface GAGs in
the initial binding step of DEN and YF virus to cultured
mammalian cells [41–43]. Cell-surface GAGs such as
heparan sulfates are present on many cell types and are
commonly bound by pathogens as a first step of cell pene-
tration [44]. Mosquito cells appear to have the genetic
capability to synthesize GAGs [45] and were shown to
possess homologues of low density lipoprotein receptor
(LDL-R) and the tetraspanin receptor [46, 47]. Presum-
ably, these are the steps required to initiate infection of
mosquito cells. The specificities of both the E proteins
and their cellular receptors have not been established in
detail to date, and it is not clear whether or not the same
cellular receptors exist in vertebrates (other than primates)
and in mosquito cells, or if the receptors are conserved in
all mosquito tissues [48]. It’s worth noticing that, by using
flow cytometry and an anti-CD81 human monoclonal
antibody, we did not succeed to show CD81 expression at
the surface of Aedes cells [22].
Cell lines of the mosquito species Aedes aegypti and
Aedes albopictus are known to replicate diverse viruses
belonging to the Flavivirus family [49]. We chose these
two cell lines, because these two species of Aedes mosqui-
toes are rapidly expanding their territory around the globe
and penetrate the developed countries in Europe, Asia
and North America, partly due to ecological changes such
as global warming [50, 51]. We focused on the infection
protocol according to that published before with HepaRG
cells (23, and user guide for HepaRG® culture kit 902 for
Fig. 6 Phylogenetic analysis of uniquely represented sequences from the NGS data set. The clades of each reconstructed tree are identified to
their majority group (Lat inoculum, HCV-infected samples at D21 and/or D28 p.i.). a Divergent evolution of viral strains in Lat and HepaRG (H)
hosts (H). b Divergent evolution of viral strains in Lat and Ktmos1 (K) hosts. c Lack of evidence for divergence in C6/36 (c) hosts. The pie charts
show the proportion of each group in each reconstructed phylogenetic clade
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HCV infection, Biopredic International), demonstrating
intracellular HCV RNA detection at days 21 and 28 p.i
with concomitant production of enveloped HCV infec-
tious particles. This entire work has then been adapted to
the C6/36 mosquito cell line and to the original Ktmos1
cell line, developed in our laboratory (see Additional file 2:
Figure S1). From the present work it was possible to con-
clude that the cells from the mosquitoes Aedes albopictus
(C6/36 cells) and Aedes aegypti (Ktmos1) could be in-
fected by serum-derived HCV particles, as viral RNA (+)
was detectable at days 21 and/or 28 p.i. To ascertain such
a replication, we performed NGS completed with statis-
tical methods computationally very efficient to study RNA
virus evolution [52, 53]. Interestingly, similar results were
obtained with both human HepaRG hepatocytes and Ae
aegypti mosquito cells. One of the major results we got in
this study is the selection for a HCV quasispecies in Aedes
aegypti cells, with an increase of global viral diversity sug-
gesting a structuration of the population with elimination
of deleterious mutations. The evolutionary pattern in Ae
albopictus is different (stability of viral diversity and poly-
morphism), but all in all, these results strongly suggest
that the HCV is capable to replicate, not only within hu-
man hepatocytes but also within cells from Aedes cells.
In 2011, the first HCV homolog was reported in dogs
but subsequent studies showed the virus to be widely
distributed in horses, as well [54]. This indicated a wider
Hepacivirus host range than previously assumed, and
paved the way for identification of rodent, bat and non-
human primate Hepaciviruses [55, 56]. An entirely open
question remained how long-term endemic transmission
of HCV is maintained, and there have been very few at-
tempts to redress the paucity of the available data which
could clarify this important issue. In an investigation pub-
lished in 2007, Pybus and colleagues utilized a combined
approach integrating bioinformatics and geographic loca-
tion analyses to build a spatial database of endemic HCV
infections. They demonstrated that this database can be
used to geographically compare endemic HCV strains
with the range distributions of potential vector species
[57]. For HCV, well established routes of transmission
comprise blood products, drug addiction, sexual transmis-
sion and the nosocomial context. Nevertheless, the origin
of a significant fraction of HCV infections in humans
today remains unexplained, and in fact none of the condi-
tions listed above apply. Moreover, a high prevalence of
HCV infection has been observed in hot, humid regions,
such as Egypt and in Southern Japan. At the present time,
no viable explanation has been put forward for this geo-
graphical distribution of the disease. We hypothesize that
possibly arthropods could represent the elusive sanctuary.
For instance, mosquitoes may be the most common vector
responsible for epidemic disease caused by the Flavi-
viruses. In the present study we have demonstrated that
cell lines from two different mosquitoes, which are rapidly
spreading towards developed countries, efficiently associ-
ate with recombinant bacHCVpp expressing E1E2 enve-
lope proteins, suggesting that HCV amplification may be
possible via Aedes mosquitoes. More conclusive, we com-
pleted this first approach by infection experiments study-
ing the dynamics of viral strains over the course of HCV
infection.
Conclusions
We provide, for the first time, credible experimental
evidence that HCV could indeed exist in Aedes mosqui-
toes. Our results suggest that these mosquito species
may be bona fide vectors responsible for the hidden
HCV epidemic, a discovery with major implications for
public health and control strategies. Finally our findings
provide the basis for a new and deeper probe into the
patterns, prevention and treatments of HCV, including
a strong focus on arthropodes in future studies.
Additional files
Additional file 1: Table S1. Characteristics of HCVs Lat strain used for
binding/infection experiments. (DOCX 32 kb)
Additional file 2: Figure S1. Global process of the Ktmos1 cell
generation from eggs hatching to the final supracellular structures. (A)
Macroscopic picture showing the eggs of Aedes aegypti collected from
insectary. (B) Large hollow vesicles developing at the cut ends of the
larvae fragments. (C) Microscopic examination of the adherent cells and
molecular identification of cells and larvae extracts by PCR targeting
rDNA ITS: the upper panel shows cells in monolayer; the lower panel
indicates species-diagnosis PCR of cellular samples with hollow vesicles
(lane 1), adherent cells (lane 2) and “Dome-like” structures (lane 3). HEK
293 cells are the negative control, ground larvae extracts of Aedes aegypti
bora bora strain are the positive control. The approximate size of the
amplified product is 550 pb. (D) Microscopic examination of the hollow
vesicles as supracellular structures (D1 and D2). (TIFF 751 kb)
Additional file 3: Figure S2. Fluorescence observation of adherent
Ktmos1 cells. The Ktmos1 Aedes aegypti cells were grown on thin glass
(0,17 mm), 2 chambers LabTek (Nunc). The cells were fixed after different
periods of cultivation with 2% PFA for 20 min at 37 °C. After
permeabilization by PBS containing 0,1% Triton X100 for 2 min, the
nuclei were stained by Hoechst 33,258 (Sigma). Observation was
performed on motorized inverted Olympus IE81 microscope using the
DIC (Differential Interference Contrast) and the DAPI filter. The panel (A)
shows a late metaphase stage of a dividing cell. The panel (B) shows
Ktmos1 cells in monolayer. (TIFF 925 kb)
Additional file 4: Figure S3. Characteristics of the bacFlu-VLPs. Panel A
Coomassie stained SDS-PAGE of the bacFlupps showing the influenzavirus
glycoproteins HA0, HA1 and gp139 (panel A). Panels B and C exhibit EM
structures of a genuine influenzavirus particle (Courtesy of Rob Ruigrok
Université Grenoble Alpes) and Flu-VLPs used in this study, respectively.
(TIFF 2540 kb)
Additional file 5: Figure S4. HCV Infection protocols. (A) for human
HepaRG hepatocytes (“H”) and (B) for insect cells, Ktmos1 (“K”, Ae Aegypti)
and C6/36 (“C”, Ae Albopictus). The infection was performed using HCVsp,
LAT isolate, genotype 3. D, day; − before infection; D0, day of infection;
D4, D7, D14, D21, D28, days post-infection and medium change. P17,
P18, passages 17 and 18. HepaRG®, HepaRG cells from KIT902 (Biopredic
International). Over the time, HepaRG and Ktmos1 cells in monolayer
became more and more differentiated. (TIFF 300 kb)
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Additional file 6: Figure S5. Mutations in the HCV IRES region in HCV-
infected cells. (A) Structure of HCV IRES region. (B) Mutations observed in
HCV-infected HepaRG (H), Ktmos1 (K) and C6/36 (C) cells at days 21 (H21,
C21) and 28 (H28, K28, C28) p.i. in the IRES region of the HCV genome.
Sequencing by the Sanger method of amplification long products.
(TIFF 847 kb)
Additional file 7: Figure S6. Absence of HCV RNA detection in HEK
293 cells. Cells were collected at days 0 (D0), 4 (D4), 21 (D21) and 28
(D28) p.i. The inoculum HCVsp (LAT isolate, genotype 3) was used as
positive control. Non-infected (mock) cells (−) and HCV-infected (+) HEK
293 cells. (TIFF 1236 kb)
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